Piperacillin/Tazobactam is a combination antibiotic containing the extended-spectrum penicillin antibiotic piperacillin and the ß-lactamase inhibitor tazobactam. Piperacillin has an antimicrobial activity against a wide range of gm-ve organisms including K. pneumoniae, P. aeruginosa, Enterobacteriaceae and against In combination, tazobactam enhances the activity of piperacillin against beta-lactamase-producing bacteria.
Piperaciilin exerts bactericidal activity by inhibiting septum formation and cell wall synthesis of susceptible bacteria. Piperacillin/tazobacatam has been shown to be active against most strains of the following micro-organism : aerobic and facultative gram-positive micro-organism, staphylococcus aureus. gm+ve organisms eg E. faecalis and B. fragilis. Tazobactam is a penicillanic acid sulfone derivative with beta-lactamase inhibitory properties.
Piperacillin and Tazobactam for injection is a combination product consisting of a penicillin-class antibacterial, piperacillin, and a ß-lactamase inhibitor, tazobactam, indicated for the treatment of patients with moderate to severe infections caused by susceptible isolates of the designated bacteria in the conditions listed below.
Appendicitis (complicated by rupture or abscess) and peritonitis caused by ß-lactamase producing isolates of Escherichia coli or the following members of the Bacteroides fragilis group: B. fragilis, B. ovatus, B. thetaiotaomicron, or B. vulgatus. The individual members of this group were studied in fewer than 10 cases.
Skin and Skin Structure Infections
Uncomplicated and complicated skin and skin structure infections, including cellulitis, cutaneous abscesses and ischemic/diabetic foot infections caused by ß-lactamase producing isolates of Staphylococcus aureus.
Female Pelvic Infections
Postpartum endometritis or pelvic inflammatory disease caused by ß-lactamase producing isolates of Escherichia coli.
Community-acquired pneumonia (moderate severity only) caused by ß-lactamase producing isolates of Haemophilus influenzae.
Nosocomial pneumonia (moderate to severe) caused by ß-lactamase producing isolates of Staphylococcus aureus and by piperacillin/tazobactam-susceptible Acinetobacter baumannii, Haemophilus influenzae,Klebsiella pneumoniae, and Pseudomonas aeruginosa (Nosocomial pneumonia caused by P. aeruginosashould be treated in combination with an aminoglycoside).
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Piperacillin and Tazobactam for injection and other antibacterial drugs, Piperacillin and Tazobactam for injection should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Tazodis is contraindicated in patients with a history of allergic reactions to any of the penicillins and/or cephalosporins or ß-lactamase inhibitors.
Tazodis injection is available as vial with WFI, tray and outer carton.